247 related articles for article (PubMed ID: 26041010)
1. Pleomorphic spindle cell dermal neoplasm with dot-like keratin reactivity: keratin-positive AFX or carcinoma?
Ellis R; Chase E; Barland A; Rajpara A; Fraga GR
J Cutan Pathol; 2015 Nov; 42(11):847-52. PubMed ID: 26041010
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
3. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma.
Gleason BC; Calder KB; Cibull TL; Thomas AB; Billings SD; Morgan MB; Hiatt KM; Smoller BR
J Cutan Pathol; 2009 May; 36(5):543-7. PubMed ID: 19476522
[TBL] [Abstract][Full Text] [Related]
4. Atypical fibroxanthoma/malignant fibrous histiocytoma.
Marcet S
Dermatol Ther; 2008; 21(6):424-7. PubMed ID: 19076618
[TBL] [Abstract][Full Text] [Related]
5. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma.
Wieland CN; Dyck R; Weenig RH; Comfere NI
J Cutan Pathol; 2011 Nov; 38(11):884-8. PubMed ID: 21883368
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma.
Bull C; Mirzabeigi M; Laskin W; Dubina M; Traczyc T; Guitart J; Gerami P
J Cutan Pathol; 2011 Aug; 38(8):631-5. PubMed ID: 21623867
[TBL] [Abstract][Full Text] [Related]
7. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.
Kanner WA; Brill LB; Patterson JW; Wick MR
J Cutan Pathol; 2010 Jul; 37(7):744-50. PubMed ID: 20184665
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid Carcinoma With Quasi-Complete Loss of Cytokeratin Expression or Keratin-Positive Atypical Fibroxanthoma.
Roy SF; Lafaille P; Désy D
Int J Surg Pathol; 2019 Aug; 27(5):518-520. PubMed ID: 30760056
[TBL] [Abstract][Full Text] [Related]
9. Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX.
Harding-Jackson N; Sangueza M; Mackinnon A; Suster S; Plaza JA
Am J Dermatopathol; 2015 Jul; 37(7):509-14; quiz 515-6. PubMed ID: 26098709
[TBL] [Abstract][Full Text] [Related]
10. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
11. Atypical fibroxanthoma: new insights.
Hussein MR
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1075-88. PubMed ID: 24958232
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical distinction of cutaneous spindle cell carcinoma.
Morgan MB; Purohit C; Anglin TR
Am J Dermatopathol; 2008 Jun; 30(3):228-32. PubMed ID: 18496422
[TBL] [Abstract][Full Text] [Related]
13. The many faces of Atypical fibroxanthoma.
Agaimy A
Semin Diagn Pathol; 2023 Jul; 40(4):306-312. PubMed ID: 37438163
[TBL] [Abstract][Full Text] [Related]
14. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
15. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
Miller K; Goodlad JR; Brenn T
Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma detected by high-molecular-weight cytokeratin immunostaining mimicking atypical fibroxanthoma.
Gray Y; Robidoux HJ; Farrell DS; Robinson-Bostom L
Arch Pathol Lab Med; 2001 Jun; 125(6):799-802. PubMed ID: 11371235
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Atypical Fibroxanthoma Versus Malignant Fibrous Histiocytoma.
Branch LG; Albertini JG; Leshin B
J Craniofac Surg; 2015 Jun; 26(4):e322-3. PubMed ID: 26080249
[TBL] [Abstract][Full Text] [Related]
18. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma.
Dotto JE; Glusac EJ
J Cutan Pathol; 2006 Jun; 33(6):413-7. PubMed ID: 16776716
[TBL] [Abstract][Full Text] [Related]
19. [Atypical fibroxanthoma and pleomorphic dermal sarcoma].
Ziemer M; Jäger IM; Dippel E
Hautarzt; 2019 Sep; 70(9):661-669. PubMed ID: 31468069
[TBL] [Abstract][Full Text] [Related]
20. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
Hartel PH; Jackson J; Ducatman BS; Zhang P
J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
